Background

Chronic periodontitis has an interplay between different species of bacteria found in dental biofilms act a crucial role in pathogenesis and disease progression. The existing antibacterial therapy is inadequate, associated with many side effects as well as evolving multidrug resistance. Hence, novel drugs development with minimum or no toxicity is an immediate priority.

Methods

Antibacterial efficacy of ethanolic extract of Matricaria aurea was tested against clinical isolates, ie. Treponema denticol, Tannerella forsythia, Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis from the patients with chronic periodontitis. Zone of inhibition, the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) were investigated by well diffusion method and micro broth dilution assay using alamar blue. Anti-virulence properties of the extract, which include adherence property and the biofilm formation, were investigated by adherence as well as biofilm formation assay.

Results

Matricaria aurea extract showed potent inhibitory effect against pathogenic periodontal bacteria with the significant inhibitory zone (13–23 mm), MIC (0.39–1.56 mg/ml) as well as MBC (1.56–6.25 mg/ml). The M. aurea extract was able to inhibit bacterial adhesion ranged from 30 to 45%, 35 to 63% and 55 to 80% of MIC at MIC × 0.5, MIC × 1 and MIC × 2 respectively. Significant inhibition was found in biofilm formation to all the tested periodontal bacterial strains after the treatment with various concentrations of M. aurea extract for 24 and 48hrs.

Conclusion

These results reveal for the first time that the Matricaria aurea extract might be the source of various compounds to be applied for chronic periodontitis therapy, which might draw these valuable compounds to the subsequent phase of development of the drug.

中文翻译：

---

母菊对牙周炎患者临床分离株的抗菌性能评价，特别是红色复合菌

背景

慢性牙周炎在牙齿生物膜中发现的不同种类的细菌之间存在相互作用，在发病机制和疾病进展中起着至关重要的作用。现有的抗菌疗法不足，伴随着许多副作用以及不断发展的多药耐药性。因此，开发毒性最小或无毒性的新药是当务之急。

方法

母菊乙醇提取物的抗菌功效针对临床分离物进行了测试，即。来自慢性牙周炎患者的牙齿密螺旋体、连翘坦纳菌、伴放线聚合杆菌和牙龈卟啉单胞菌。通过孔扩散法和使用alamar blue的微量肉汤稀释法研究抑制区、最小抑制浓度(MIC)和最小杀菌浓度(MBC)。通过粘附以及生物膜形成测定法研究了提取物的抗毒​​力特性，包括粘附特性和生物膜形成。

结果

母菊提取物对病原性牙周细菌显示出有效的抑制作用，具有显着的抑制区（13-23 mm）、MIC（0.39-1.56 mg/ml）和 MBC（1.56-6.25 mg/ml）。在 MIC × 0.5、MIC × 1 和 MIC × 2 时，M. aurea提取物能够抑制 MIC 的 30% 至 45%、35% 至 63% 和 55% 至 80% 的细菌粘附。在用不同浓度的金黄色葡萄球菌提取物处理24小时和48小时后，发现对所有测试的牙周细菌菌株的生物膜形成有显着抑制作用。

结论

这些结果首次揭示了母菊提取物可能是用于慢性牙周炎治疗的各种化合物的来源，这可能会将这些有价值的化合物吸引到药物的后续开发阶段。